News

BBJ: Md. Tech Council CEO wants state biotech industry to aim higher than “top 3”

MTCjpg

“Why would you shoot for No. 3?” Maryland Tech Council CEO Marty Rosendale wants to unite companies and legislators around making Maryland into the No. 1 destination for biotech firms in the U.S. Click here to read more via the Baltimore Business Journal (Subscription Required)

Comments Off on BBJ: Md. Tech Council CEO wants state biotech industry to aim higher than “top 3” Continue Reading →

3-V Biosciences Changes Name to Sagimet Biosciences and Closes $25 Million Financing

Sagimet Biosciences Logo

Name connotes expertise in fatty acid metabolism and therapeutic focus targeting dysfunctional metabolic pathways SAN MATEO, Calif., Aug. 5, 2019 /PRNewswire/ — 3-V Biosciences, a clinical-stage biotechnology company, announced today that it has changed its name to Sagimet Biosciences and closed a second tranche of its Series E financing, which now totals $25 million. Sagimet’s lead product candidate, the […]

Comments Off on 3-V Biosciences Changes Name to Sagimet Biosciences and Closes $25 Million Financing Continue Reading →

MaxCyte Founder, President and CEO Doug Doerfler joins Rich Bendis on BioTalk

BioTalk Logo

MaxCyte Founder, President and CEO Doug Doerfler joins BioTalk to discuss his history and the growth of the company. He also shares advice for entrepreneurs Mr. Doerfler has more than 35 years of experience in the discovery, development, commercialization and international financing of biotechnology products and companies. He was a founder of MaxCyte in July […]

Comments Off on MaxCyte Founder, President and CEO Doug Doerfler joins Rich Bendis on BioTalk Continue Reading →

MaxCyte Adds VP, Non-Clinical and Translational Studies, to Support Advancement of Programs from Its CARMA™ Platform

2X2 Final MaxCyte Portrait July 1 2019 DSC_1669 Coyle Studios

Dhana Chinnasamy, PhD, will oversee non-clinical and translational activities for MaxCyte’s autologous cell therapy platform for targeted cell-based immune therapies  Gaithersburg, Maryland – July 23, 2019: MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announced today that it has appointed Dr. Dhana Chinnasamy, a 20+-year expert in the research and translation of gene and […]

Comments Off on MaxCyte Adds VP, Non-Clinical and Translational Studies, to Support Advancement of Programs from Its CARMA™ Platform Continue Reading →

BioBuzz: Five Companies That Are Powering The Cell and Gene Therapy Revolution (MaxCyte Included)

MAXCYTE-New-Logo-2016-LARGE

Several Maryland companies are making a global impact in the field of cell and gene therapy July 16, 2019 The promise of cell and gene therapies to cure unmet medical needs is finally starting to come through as life-saving new medicines are now hitting the market every year. The global market for gene therapies was […]

Comments Off on BioBuzz: Five Companies That Are Powering The Cell and Gene Therapy Revolution (MaxCyte Included) Continue Reading →

Genomics leader Illumina is opening a new center at University of Maryland BioPark

UMBioPark-Twitter-Profile-Image

It’s the first East Coast location for the San Diego-based company. Here’s how leaders say it can raise the profile for Baltimore’s biotech community. A leading genomics company with international reach is opening its first commercial location on the East Coast at Baltimore’s University Maryland BioPark. San Diego-based Illumina, which was founded in 1998 and has 7,000 […]

Comments Off on Genomics leader Illumina is opening a new center at University of Maryland BioPark Continue Reading →

GlycoMimetics CEO Rachel King Featured in Article on Uproleselan

RachelKing

In Cancer, Boosting Chemotherapy while Reducing Toxic Side Effects is a Potential Breakthrough GlycoMimetics is conducting a pivotal Phase 3 trial in the US, Europe and Australia to determine if its drug candidate, uproleselan, can successfully treat patients with relapsed and refractory acute myeloid leukemia (AML), a blood cancer. The unique aspect of uproleselan is […]

Comments Off on GlycoMimetics CEO Rachel King Featured in Article on Uproleselan Continue Reading →

MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform

MAXCYTE-New-Logo-2016-LARGE

–      No dose-limiting toxicities or safety concerns observed in first cohort of treated patients–      Feasibility of streamlined, faster CAR therapy manufacturing process confirmed–      Dosing initiated in second cohort of patients Gaithersburg, Maryland – May 8, 2019: MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announced today that it […]

Comments Off on MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform Continue Reading →

UMB startup CoapTech receives FDA clearance for feeding tube placement device

coaptech logo

The company’s device uses ultrasound, which will allow a feeding tube to be placed without need for a surgical setting. With regulatory approval, it’s taking a key step toward commercialization. Baltimore-based medical device startup CoapTech reached a key milestone in April: It can now market its product that allows the placement of a feeding tube without the […]

Comments Off on UMB startup CoapTech receives FDA clearance for feeding tube placement device Continue Reading →

MaxCyte Presents at 22nd Annual ASGCT Meeting on Manufacturing Process for First CARMA™ Drug Candidate, Including One-Day Cell Processing

MAXCYTE-New-Logo-2016-LARGE

– CARMA drug candidates can be manufactured via streamlined, single-day process, providing a much needed faster turnaround of autologous cell therapy to patients– CARMA cell therapies are engineered with the intention of reducing potential adverse events that have been evident with other CAR technologies and to allow for multiple dosing, an important feature for potential […]

Comments Off on MaxCyte Presents at 22nd Annual ASGCT Meeting on Manufacturing Process for First CARMA™ Drug Candidate, Including One-Day Cell Processing Continue Reading →